KDM4B protects against obesity and metabolic dysfunction

Area of Science:

• Epigenetics
• Metabolic Regulation
• Obesity Research

Background:

• Epigenetic regulation of adipogenesis is understood in vitro, but in vivo roles in metabolism and obesity are unclear.
• Lysine demethylase 4B (KDM4B) is an epigenetic regulator with largely unknown physiological functions in metabolism.

Purpose of the Study:

• To investigate the physiological role of KDM4B in adipose tissue concerning energy balance, metabolism, and obesity.
• To determine if KDM4B acts as a therapeutic target for obesity and related metabolic dysfunctions.

Main Methods:

• Utilized mouse models with KDM4B deficiency (both global and adipocyte-specific).
• Assessed metabolic parameters including energy expenditure, thermogenesis, lipolysis, and glucose/lipid metabolism.
• Analyzed gene expression changes, focusing on metabolic regulators like Ppargc1a and Ppara.

Main Results:

• KDM4B deficiency in mice led to obesity, reduced energy expenditure, and impaired adaptive thermogenesis.
• KDM4B-deficient mice exhibited hyperlipidemia, insulin resistance, and hepatic/pancreatic pathologies.
• Adipocyte-specific KDM4B deletion confirmed adipose tissue as the primary site for its anti-obesity effects.
• KDM4B directly regulates key metabolic genes, including Ppargc1a and Ppara.

Conclusions:

• KDM4B is an essential epigenetic factor regulating metabolic health and maintaining normal body weight in mice.
• KDM4B in adipose tissue plays a critical role in energy homeostasis, oxidation, lipolysis, and thermogenesis.
• KDM4B represents a potential therapeutic target for the treatment of obesity and associated metabolic diseases.